Vanguard Global Advisers
ELDN icon

Vanguard Global Advisers’s Eledon Pharmaceuticals ELDN Stock Holding History

Vanguard Global Advisers’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.2K Buy
24,936
+2,705
+12% +$9.84K ﹤0.01% 2789
2026
Q1 		$68.5K Buy
+22,231
New +$52.4K ﹤0.01% 2880

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Vanguard Global Advisers's ELDN Position: Q2 2026 in Review

Vanguard Global Advisers increased its Eledon Pharmaceuticals (ELDN) stake by 12% in Q2 2026, buying an estimated $9.84K and bringing the position to 24,936 shares worth $98.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2789.

Vanguard Global Advisers first reported a position in ELDN in Q1 2026 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Vanguard Global Advisers held 24,936 shares of Eledon Pharmaceuticals worth $98.2K as of Q2 2026.
  • Vanguard Global Advisers bought 2,705 Eledon Pharmaceuticals shares in Q2 2026, an estimated $9.84K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2789 holding.
  • Vanguard Global Advisers first reported a position in Eledon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 158 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.